Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | -0.59% | +1.35% | +18.59% |
13/05 | Merck: phase 3 trial in melanoma halted | CF |
13/05 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
Official Publications
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 10Q-1 | CO | |
Slide show Q1 | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
Proxy Statments | CO | |
Annual ESG Report | CO | |
SEC Filing 10K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 13G | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 8K | CO | |
Dividends | CO | |
Slide show Q3 | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO | |
Slide show half-year results | CO | |
1st-half-year results | CO | |
SEC Filing 8K | CO |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Official Publications